MF-ADC

MF-ADC:

One leading product TCI-212 is in the mid-late preclinical stage of developmen

TCI-212
  • Novel design of long-acting monovalent multi functional antibody targeting EGFR, cMet, PDL1 and PDL2TCI
  • Integrates tumor-specific cytotoxicity with immune checkpoint blockade
  • Potentially addresses tumor heterogeneity and overcomes drug resistance
  • Optimized binding affinities for each target to balance efficacy and safety
  • Highly homogeneous conjugated product (DAR=4) with excellent stability
  • Expanded therapeutic window compared to conventional therapies
  • Compatible with combination therapy alongside TKIs
  • Demonstrates target-antigen-dependent cytotoxicity, with tumor cell killing strictly correlated to TAA expression levels
Scroll to Top